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 Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease leading to 
decreased lung volume and eventual respiratory failure. At present, the median 
post-diagnosis lifespan is between three and six years. Myofibroblasts are 
collagen-secreting cells essential for wound healing, but also implicated in the 
fibroproliferation and extra cellular matrix deposition commonly seen in IPF.  The 
nitric oxide (NO) signaling pathway is implicated in protomyofibroblast to 
myofibroblast transition and regulation. Previous work has shown that in 
pulmonary myofibroblasts, endothelial nitric oxide synthase (eNOS) is the 
primary NOS isoform expressed. The current study used cultured rat pulmonary 
myofibroblasts between passages two and five as a cell model. The cells were 
grown in normal growth media (DMEM + 10% FBS) or serum starved (DMEM + 
0% FBS) to induce cellular differentiation. In this study, immunocytochemistry 
was used to show localization of eNOS is dependent on cellular differentiation, 
with protomyofibroblasts expressing eNOS primarily in the nucleus and 
protomyofibroblasts expressing eNOS in the perinuclear region. We also show 
catalytic activity and localization of eNOS are correlated by visualizing nitric oxide 
production in the cells using a permeable fluorescein chromophore. By using 
western blot analysis on fractionated cell lysates we found eNOS expressed in 
   viii 
the nucleus under normal growth conditions. eNOS is at least partially regulated 
by intracellular calcium (Ca2+) and calmodulin (CaM). Western blot analysis using 
native eNOS and phospho-specific eNOS antibodies on fractionated cells treated 
with the protein kinase C (PKC) activator phorbal 12-myristate 13-acetate (PMA) 
with and without addition of its antagonist ethylene glycol tetraacetic acid (EGTA) 
was conducted to investigate PKC’s role in eNOS regulation by phosphorylation. 
Indeed, PKC activation was found to mitigate expression in the nucleus, while 
inhibition of the activator restored the activity expression above basal levels. This 
finding correlates with previous data from our lab showing a decrease in activity 
in myofibroblasts treated with PMA and assayed amperometrically with an NO 
electrode. 
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INTRODUCTION 
 
Idiopathic Pulmonary Fibrosis 
 Idiopathic pulmonary fibrosis (IPF) is characterized by actively proliferating 
myofibroblasts and a subsequent uncontrolled release of extracellular matrix 
(ECM) proteins in pulmonary tissue, driving the destruction of the lung 
parenchyma architecture (Selman et al., 2001). Exertional dyspnea and chronic 
cough account for around 90% of the initial symptoms, and diagnostic 
confirmation is typically performed via a lung biopsy and chest radiographs, 
which show bilateral peripheral based reticular opacities and honeycombing 
predominately in the lower lobes (Figure 1). The American Thoracic Society and 
European Respiratory Society established international guidelines in 1999 
regarding the diagnostic criteria that must be present for the confirmation of IPF. 
Briefly, a definitive diagnosis can be established in the presence of a surgical 
biopsy that includes the following:  
1. Exclusions of other known causes of interstitial lung disease such as drug 
toxicities, environmental exposures, and collagen vascular diseases  
2. Abnormal pulmonary function studies that include evidence of restriction 
and/or impaired gas exchange with rest or exercise or decreased carbon 
dioxide diffusing capacity of the lung  
3. Abnormalities on conventional chest radiographs or high-resolution 
computed tomography scans (IPF: Diagnosis and Treatment 1999)  
   2 
 
Figure 1: (A) Normal lung radiograph (BMJ publishing group, 2002). (B) 
Radiograph of patient with IPF. Bilateral scarring and honeycombing is prominent 
(Heilman, 2010)  
 Prevalence based on a cohort study from the years 1996 to 2000 was 
found to range from 4.0 per 100,000 persons aged 18-34 years to 227.2 per 
100,000 persons among those 75 years and older (Raghu et al., 2006). 
Prognosis for those suffering from IPF, while displaying a fairly large 
heterogeneity depending on the time of diagnosis and subsequent treatment, is 
generally poor, with a post-diagnosis life span of three to six years (Bjoraker et 
al., 1998; Johnston et al., 1997; Gay et al., 1998).  
 IPF is thought to be a deleterious consequence of unresolved pulmonary 
inflammation that can be stimulated from various causative agents, including 
preexisting disease, acute illness and injury. Normally, patients are treated with 
anti-inflammatory therapies and show improvement in the days to weeks 
following diagnosis. However, a small number of these patients will progress 
towards chronic fibrosis, eventually showing the excessive ECM deposition and 
honeycombing of the lung. Patients presenting with IPF only respond mildly at 
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best to treatment with anti-inflammatory agents such as corticosteroids (Selman 
et al., 2002). It should be noted, however, that early in vivo characteristics of IPF 
show similarities to non-pathogenic usual interstitial pneumonia (UIP), so much 
so, in fact, that early stage identification of IPF cannot be readily distinguished 
from UIP (Nicholson et al., 2000). The unfortunate distinction that separates 
patients suffering from true IPF from those with UIP is death following the lack of 
physiological response to currently accepted treatment measures with high dose 
corticosteroids, such as prednisone and a supplemental cytotoxic 
immunosuppresent (Rhagu, 2006; Rudd et al., 1981; Johnston et al., 1991). This 
resistance to conventional treatment demands investigation into alternative 
therapeutic targets.    
 
Cell biology of the myofibroblast 
 As a primitive mesenchyme-derived cell, myofibroblasts are a key part of 
normal tissue development. The initial identification of the myofibroblast came via 
electron microscopy, and was seen in the granulation tissue of healing wounds 
as a modulated fibroblast (Desmoulière & Gabbiani, 1996). This fibroblast-like 
cell exhibited features of smooth muscle cells, including bundles of 
microfilaments with dense bodies scattered in between and gap junctions 
(Desmouliere et al., 2007). Myofibroblastic modulation of fibroblastic cells begins 
with the appearance of the protomyofibroblast. Differentiation from 
protomyofibroblast to myofibroblast is characterized by the expression of alpha-
smooth muscle actin (α-SMA) in the cell. The appearance of these 
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microfilaments with dense bodies suggests that myofibroblasts are responsible 
for the production of the force causing wound contraction (Desmouliere & 
Gabbiani, 1996). The mechanism behind the further modification of the 
protomyofibroblast to myofibroblast is not well known, but evidence has been 
shown correlating the differentiation with the production of transforming growth 
factor-beta (TGF-β) by inflammatory cells as well as products of other fibroblasts 
(See Figure 2) (Desmouliere et al., 1993). In the lung in particular, they play an 
important role in alveolar development and are necessary for the proper repair of 
tissues during wound healing and general tissue homeostasis (Walker, et al 
2000). During wound healing, repair takes place in a well known, linear fashion: 
clots form, inflammatory cells invade injured tissues, fibroblasts migrate and 
begin the proliferation of extracellular matrix (ECM) components, the wound 
closes and, following the degradation of ECM, a scar forms (Desmoulière & 
Gabbinani, 1996).  
 While myofibroblasts are typically identified by α-SMA expression, 
expression of other sarcomeric proteins should be considered for their role in the 
myofibroblast’s contractile funtions.  Rice and Leinwand (2003) demonstrated 
that pulmonary myofibroblasts express three of the six skeletal isoforms of heavy 
chain myosin, including two adult isoforms, IIa and IId, and the developmental 
embryonic isoform. Inhibition of skeletal myosin activity significantly reduces 
contractile ability in the myofibroblast, an essential function in their ability to 
generate tensile forces in wound healing and contracture (Rice & Leinwand, 
2003).    
   5 
 
Figure 2: Fibroblast to myofibroblast transition (Adapted from Desmoulière et al., 
2005) 
 
The myofibroblast and IPF 
 In 1991, Kuhn and McDonald observed a matrix of fibronectin-containing 
fibrils, and among them myofibroblasts with well-formed actin filament bundles in 
biopsied lung tissue of seven patients suffering from usual interstitial pneumonia 
or bronchiolitis obliterans organizing pneumonia. These fibronectin-containing 
fibrils linked cells and collagen bundles and were structurally similar to the 
contractile phase seen in wound healing. This provided evidence that active 
fibroblast contraction plays a role in the remodeling lung tissue during pulmonary 
fibrosis (Kuhn & McDonald, 1991). 
 Further evidence of the fibroblast/myofibroblast role in IPF has been 
demonstrated by microarray analysis of pulmonary tissue from bleomycin-
induced fibrotic mice. A drastic increase was noted in genes expressing 
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inflammatory mediators, components of the ECM and transforming growth factor-
β1 (TGF-β1). The murine evidence was taken into consideration in the further 
identification of increased gene expression among tissue samples taken from five 
patients afflicted with IPF. In correlation with the IPF animal model, genes 
encoding proteins expressed in smooth muscle differentiation and muscle 
contractile machinery were identified in the samples, representing transcriptional 
signals of myofibroblasts and fibroblasts in the myofibroblast/fibroblast foci 
typically seen in the disease. Also observed was an increased transcription of 
genes encoding ECM proteins in fibrotic lungs (Kaminski, IPF supplement 2003). 
 Histologically, IPF is distinct from other idiopathic interstitial pneumonias in 
that it is a temporally heterogeneous disease. Temporal heterogeneity indicates 
various levels of injury within the same tissue biopsy, as opposed to temporal 
homogeneity, in which the age of lung injury is approximately the same in each 
tissue sample. Biopsies of IPF-associated lung tissues exhibit interstitial collagen 
accumulation in the same specimen where there is end-stage honeycomb lung 
(chronic injury) and active fibrosis (acute injury). The fibroblasts present in the 
actively proliferating fibrotic foci are responsible for ECM deposition, 
inflammation, and altered mechanical properties in the fibrotic lesions (Dacic & 
Yousem, IPF supplement, 2003). An imbalance between ECM component 
production and degradation due to a decrease in normal cellular apoptosis is a 
significant problem associated with IPF. Increased ECM remodeling in IPF lungs 
has also been found to correlate with imbalances in matrix metalloproteinase 
(MMP) family components, notably an increase in tissue inhibitors of 
   7 
metalloproteinase (TIMPs) (Ramos et al., 2001). MMPs are responsible for 
degradation of ECM components. TIMPs, in their active form, are inhibitors of 
MMP catalytic activity. While the process is largely unknown, this is yet further 
evidence of the role fibroblasts play in the overproduction of ECM components 
and expanse of fibrotic foci.  
 Zhang and colleagues (1994) found an increase in the amount of 
myofibroblasts in bleomycin-induced fibrotic lungs of mice, establishing the 
correlation between the amount of actively proliferating myofibroblasts and 
increased level of disease (Zhang et al., 1994). This evidence helped establish 
the correlation between concentrations of myofibroblasts in their contractile 
phase and poorer prognosis in subjects with IPF (King et al., 2001). In normal 
tissues, myofibroblasts appear transiently and are responsible for the production 
of new collagen and fibronectin at the leading edge of the healing wound. 
Myofibroblasts in other forms of organizing pneumonias have been shown to 
undergo normal apoptosis, whereas those associated with IPF remain. The 
increase in actively proliferating myofibroblasts, the increase in TIMPS, and the 
increased production of TGF-β, a known protector against apoptosis, shift focus 
of IPF away from a disease of abnormal inflammation to one of abnormal 
apoptosis among the myofibroblasts at the fibrotic foci (Phan, 2002).  
 
Nitric oxide signaling  
 In the late 1980s, the action of nitric oxide (NO) on relaxation of 
endothelial cells was elucidated (Palmer et al., 1987). The discovery of NO as a 
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signaling molecule led to the 1998 Nobel Prize in Physiology and Medicine. Nitric 
oxide is a free radical gas produced from the conversion of L-arginine, molecular 
oxygen (O2), and NADPH substrates to L-citrulline and NADP by a group of 
proteins known collectively as NO synthases (NOS) (Figure 3). NO synthesis 
also requires the presence of four additional cofactors (tetrahydrobiopterin (BH4), 
FAD, FMN, and iron protoporphyrin IX (heme)), as well as calmodulin. (Knowles 
& Moncada, 1994) The NO produced by the NO synthases diffuses to nearby 
smooth-muscle cells and binds to the active site heme of guanylyl cyclase. This 
stimulates the enzyme to increase production of cyclic guanidine monophosphate 
(cGMP) and ultimately activate cGMP-dependent kinases (Moncada & Higgs, 
1993; Knowles & Moncada, 1994). Three major isoforms constitute the NOS 
family: - neural NOS (nNOS), inducible NOS (iNOS), and endothelial NOS 
(eNOS). These three isoforms are products of different genes, under different 
regulation, have different localization properties, catalytic properties, and inhibitor 
sensitivity. It should also be noted that the enzymes differ in their constitutive 
(eNOS and nNOS) verses inducible (iNOS) expression, as well as their calcium-
dependence (eNOS and nNOS) or calcium-independence (iNOS) properties 
(Alderton et al., 2001). Each NOS exhibits oxygenase and reductase structures 
in which an N-terminal oxygenase domain containing binding sites for heme, 
BH4, and L-arginine is linked by a calmodulin-dependent recognition site for FAD, 
FMN and NADPH. In all isoforms, only dimeric NOSs are catalytically active.  
 Nitric oxide plays critical roles in vascular biology, including vessel 
relaxation and inhibition of platelet aggregation, as well as the regulation of 
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endothelial cell death. The loss of levels of bioavailable NO is an important 
biochemical marker of early endothelial disfunction found in cardiovascular 
diseases such as hypertension and atherosclerosis (Boo & Jo, 2003). Long-term 
inhibition of NO production in the heart leads to an increase in αSMA-positive 
myofibroblasts with associated collagen and fibronectin deposition in ischemic 
lesions (Pessanh et al., 2000). Generally, NO shows anti-fibrotic properties in a 
number of diseases by lowering the levels of differentiated myofibroblasts, levels 
of injury-inducing reactive oxygen species, and collagen deposition (Vernet et al., 
2002). 
 The formation of NO from L-arginine and NADH is an important part of 
nonspecific host immunity but also has the unique property of aiding in the 
maintenance of cell homeostasis (Mohr et al., 1996). There is significant 
evidence that NO, either delivered by NO donors or generated by NO synthases, 
initiates apoptotic cell death. The influence at which NO facilitates this apoptosis 
cascade is dependent on the relative rates of NO formation, its redox state, and 
combinations with oxygen, superoxide, and other biomolecules (Brüne et al., 
1999). This evidence suggests a role of NO in the appearance, differentiation, 
and disappearance of myofibroblasts at the wound site (Desmouliere et al., 
1995). Zhang and colleagues (1995) reported that pulmonary myofibroblasts are 
more susceptible to NO-mediated apoptosis than are undifferentiated fibroblasts 
(Zhang et al., 1995).   
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Figure 3: The NO synthase reaction. The boxed O and N atoms show the origin 
of the constituent atoms of NO (Knowles and Moncada, 1994). 
  
NO signaling and pulmonary myofibroblast accumulation 
 As discussed briefly above, there is ample support for NO-mediated 
regulation of myofibroblast accumulation and ECM deposition. Unfortunately, few 
of these studies focus on pulmonary cells. Interestingly, a number of these 
studies target the eNOS isoform with myofibroblast activity: Ruetten and 
colleagues (2005) generated knockout mice for each of the three NOS isoforms 
and demonstrated that eNOS deficient mice have an increase in interstitial 
fibrosis related to pressure overload-induced left ventricular hypertrophy (Ruetten 
et al., 2005). IPF is frequently associated with pulmonary hypertension 
characterized by an increase in mean pulmonary arterial pressure. Vascular 
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remodeling of the pulmonary artery is the underlying cause of the pulmonary 
hypertension in IPF patients and treatment with the NO synthase stimulating 
vascular endothelial growth factor (VEGF) appears to mitigate pulmonary 
hypertension by reducing endothelial apoptosis, increasing vascularization, and 
reducing pulmonary arterial pressure. However, VEGF treatment also 
exacerbates IPF (Farkas et al., 2009). Multiple exposures to bleomycin will 
induce chronic fibrosis in mouse (and most likely all mammalian) lungs. eNOS 
knockout mice were observed to maintain a prolonged fibrotic foci after multiple 
bleomycin exposures, while iNOS knockouts were able to clear the fibrosis as 
easily as wildtype mice (Chung et al., 2003).   
 
eNOS activation via phosphorylation  
 Previous work has demonstrated eNOS activation via sheer stress as an 
effect of blood streaming through vascular tissues (Davies, 1995). There has 
been ample evidence implicating both an increase or decrease in eNOS catalytic 
activity due to phosphorylation of serine/threonine residues in the protein 
(Dimmeler et al., 1999; Fulton et al., 1999; Fleming & Busse, 2003). Two 
residues in particular, threonine 495 (Thr495) and serine 1177 (Ser1177) (1179 in 
bovine-derived eNOS) have been shown to have important roles in the regulation 
of eNOS catalytic activity. 
  Threonine 495 is located in the calmodulin-binding domain of eNOS and 
is phosphorylated by a constitutively active AMP-activating kinase or a protein 
kinase C (PKC). The catalytic activity of eNOS, notably a decrease in production 
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of NO, is associated with Thr495 phosphorylation and is likely explained by the 
interference with the binding of CaM to the CaM-binding domain of the eNOS 
protein (Fleming & Busse, 2003). Incubation of endothelial cells with the PKC 
activator phorbol 12-myristate 13- acetate (PMA) was shown to enhance levels of 
Thr495 (Fleming et al., 2001). 
 While the activity of eNOS was initially described to be dependent upon 
the presence of Ca2+, it is now known phosphorylation-induced activity changes 
can be accomplished without the direct increase or decrease of Ca2+ levels 
(Ayajiki et al., 1996).  Fluid shear stress generated by the viscous drag of blood 
flowing over the surface of endothelial cells results in the activation of 
phosphatidylinositol 3-kinase, which activates Akt and protein kinase A to 
phosphorylate eNOS on Ser1177 and results in an increase in eNOS activity 
(Dimmeler et al., 1999). 
 It has been observed that the phosphorylation of eNOS at one site may 
affect the phosphorylation at other sites (Bauer et al., 2003). Another serine 
residue, Ser635, is a frequently observed phosphorylated residue correlating with 
an increase in eNOS activity and often co-phosphorylated with Ser1179. 
Investigation using double phospho-mutants of eNOS where both Ser1179 and 
Ser635 were mutated to alanine or aspartic acid showed both sites contribute to 
the regulation of eNOS activity, although phosphorylation of Ser635 appears to 
have greater influence on activity than Ser1179 (Boo et al., 2006). 
 
 
   13 
eNOS localization and activity 
 eNOS localization and activity are correlated in many cells types. In 
cultured endothelial cells and intact blood vessels, eNOS is found primarily in the 
caveolae associated with the cell membrane with activity levels correlating with 
translocation to specific intracellular targets (Garçia-Cardeña et al., 1996). In 
nephritic tissues, an increase in luminal blood flow in the ascending limb of the 
loop of Henle, responsible for increasing urine concentration in mammals, 
induced translocation of eNOS from primarily diffused throughout the cell to the 
apical membrane. An increase in luminal flow was also observed to increase the 
amount of phosphorylated S1179 eNOS, coinciding with an increase in catalytic 
activity (Ortiz et al., 2004).  
 eNOS localization and expression has also been found to be altered in 
neoplastic tissues. Increased eNOS staining intensity and decreased staining 
frequency was found to correlate with decreased chance of disease-free survival, 
and increased cytoplasmic eNOS localization correlated with increased 
myometrial invasion (an indication of invasive carcinoma) in a study of 50 cases 
of endometrial carcinoma and normal endometrium (Bentz et al., 1997). A similar 
correlation between eNOS localization and breast carcinomas (Thomsen et al., 
1995) further implicates the important role NO plays in carcinogenesis.  
 It is likely that numerous events implicated in the regulation of eNOS 
activity- Ca2+/CaM binding, protein-protein interactions, phosphorylation events, 
and subcellular localization, are not necessarily independent factors but 
coordinated functions ultimately affecting the activity of the enzyme. Subcellular-
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targeted eNOS mutants show variable localization properties depending on the 
mutation generated. For example, wild-type eNOS is found in both the plasma 
membrane and Golgi complex, while a myristoylation-deficient eNOS mutant 
diffuses among the cytoplasm of the cells. This mutant is also unable to produce 
NO, while a plasma membrane-targeted mutant produced NO at higher levels 
than WT eNOS (Boo et al., 2006). 
 Changes in levels of intracellular calcium also show a relationship to 
changes in localization and activity of eNOS. Treatment of human skin-derived 
mast cells with 1 µM of the calcium ionophore A23187 showed moderate 
increases in cytoplasmic localization and pronounced increases in nuclear 
localization when analyzed via immunofluoresence. Further analysis of phospho-
specific eNOS in cells treated with A23187 indicated increased levels of 
phospho- Ser1177 eNOS in both the cytoplasmic and nuclear cellular fractions, 
suggesting that increased Ca2+ levels potentiate eNOS phosphorylation and, 
coordinately, activity (Gilchrest et al., 2004). 
 
Calcium- induced activity changes and activation by PKC 
 Previous investigations from our lab have focused on myofibroblast 
differentiation, eNOS translocation and activtiy, and the cell products implicated 
in the regulation of these events. The purpose of the present study was to use 
cellular fractionation techniques and immunoblot analysis to test the hypotheses 
that localization in pulmonary myofibroblasts is dependent on growth conditions, 
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this localization is Ca2+-dependent, and eNOS phosphorylation by PKC regulates 
localization and, coordinately, activity.  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MATERIALS AND METHODS 
 
Animals 
 Four female Lewis rats (4-6 weeks old, 75-100 g) were purchased from 
Charles River Laboratories, Willmington MA.  All animals were housed in 
appropriate biological containment facilities at Western Kentucky University and 
work was carried out in accordance with guidelines established by the 
Institutional Animal Care and Use Committee (IACUC) and the American 
Association for Laboratory Animal Science (AALAS) 
(http://www.iacuc.org/usa/htm).  
 
Establishment of primary myofibroblast cell line 
 The four Lewis rats were euthanized in order to establish a primary cell 
line to carry out subsequent work. Pulmonary fibroblasts were isolated as follows: 
a tracheal/lung lavage was performed three times with 1x Hank’s Balanced Salt 
Solution (HBSS, Invitrogen). The lungs were then gently perfused twice with 
saline containing 5 µg/mL heparin. The lungs and heart were dissected out and 
moved to a sterile dish containing cold HBSS. Each lung was then dissected free 
and placed in cold digestion media (86% 1x HBSS, 0.1% 10x trypsin, 0.02% 
DNase, 1 mg/mL collagenase, 0.025% HEPES) where they were minced. Each 
minced lung was allowed to incubate at 37˚C+5% CO2 for 30 minutes, and then 
was placed in a conical vial and vortexed vigorously for a few seconds. 
Dulbecco’s Modified Eagles Media (DMEM, Invitrogen) supplemented with 10% 
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(v/v) fetal bovine serum (FBS) and antibiotics (100 U/mL penicillin and 100 
mg/mL streptomycin) was added to each tube to halt the digestion. Tissues were 
moved to a 100 mm tissue culture dish and macerated with a sterile pipette tip 
and transferred back to a 50 mL conical tube. Contents of each tube was 
combined and centrifuged three times at 1200 RPM for 10 minutes. Between 
each centrifugation, pellets were washed with wash media (DMEM, 5% BCS, 
Pen/Strep). Cells were then counted using a hemacytometer and diluted 
accordingly for plating at a concentration of 1-2 x 105 cells/100 mm plate. Media 
was changed every morning for three to four days following prep to eliminate red 
blood cell contamination. After one week, the cells were passaged 1:3.   
 
Cryopreservation of primary myofibroblasts 
 Cells were grown in DMEM +10% FBS until they reached a concentration 
of 1-5 x 106 cells/mL. Cells were then resuspended in 1 mL cryovials of freezing 
media (90% FBS + 10% DMSO) at desired concentration and immediately 
placed in -80˚C freezer. The vials were transferred to N2 after 24-48 hours.  
 
Myofibroblast culturing 
 One 1 mL tube containing primary myofibroblasts was removed from N2 
and quickly thawed in a 37˚C water bath for 2-3 minutes. Cells were 
resuspended 1:10 in normal growth media (DMEM/10%FBS) and gently pipetted 
onto a 100 mm dish. Cells were grown to ~70-75% confluence in 37˚C+5% CO2 
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incubator, then passaged 1:4 to obtain desired concentration of cells for 
experiments. Only cells between passages 2-5 were used for all experiments.  
 
Myofibroblast harvesting and assay 
 Media was aspirated from each plate containing cells at appropriate 
confluence and 1 mL 0.05% trypsin was added and each plate is allowed to 
incubate for 30 minutes in 37˚C+5% CO2 incubator enzymatically loosen cells 
from the culture dishes. Cells were then washed sterile phosphate-buffered 
saline (PBS) and transferred to eppendorf tube, where they were pelleted via 
centrifugation and resupended in 1x lysis buffer (10 mM NaCl, 10 mM Tris-HCL 
(pH=7.6), 3 mM MgCl2, 0.5% Tween-20) supplemented with protease inhibitor 
tablet (Roche). Cells were lysed via sonication (3x pulses, 10 seconds, 60% 
amplitude). Protein concentration was obtained via DC protein assay kit (Bio-
Rad) or A280 absorbance using a Thermo Nanodrop ND-100 Spectrophotometer 
(Stoscheck, 1990).  
 
Nuclear/Cytoplasmic isolation of cell lysates 
 Fibroblasts were harvested in 5 mL sterile PBS and pelleted via 
centrifugation at 2,000 RPM for five minutes at 4°C. Cell lysates were then 
resuspended in 1x lysis buffer and allowed to incubate at room temperature for 
two minutes, then on ice for 10 minutes. Ten percent NP-40 (Sigma) was added 
to the volume of lysates to a final concentration of 1% (v/v) and the solution was 
then passed through a 20-gauge needle 2-3 times. One molar MgCl2 was added 
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to a final concentration of 5 mM and the nuclei were pelleted by centrifugation at 
600g for 5 minutes at 4°C. The cytoplasm-containing supernatant was collected 
and centrifuged at 12,000g for 5 minutes at 4°C to ensure no nuclear carryover. 
The remaining pellets comprising the nuclear fraction were washed with 300 µl 
1x lysis buffer containing 5 mM MgCl2. This wash sequence was repeated 2-3 
times, discarding the supernatant each time. The nuclei were lysed by adding 
another 300 µl of 1X lysis buffer containing 0.3% sodium dodecyl sulfate (SDS) 
to the final wash pellet and vortexing. Nuclear DNA was sheared via sonication 
on ice (10 seconds at 50% amplitude). Cytoplasmic and nuclear fractions were 
then assayed, aliquoted into working stocks, and stored at -80°C. Adequate 
fractionation was confirmed by western blot (see below) by probing with a 
proliferating cell nuclear antigen (PCNA) antibody. PCNA is a 35 kDa protein that 
accumulates in the nuclei of dividing and transformed cells (Mathews et al., 
1984) and the presence/absence of which confirms successful 
nuclear/cytoplasmic fractionation.   
 
SDS-PAGE and Western Blotting 
 Western blots were carried out using standard methods (Towbin et al., 
1979; Renart et al., 1979) with optimizations for myofibroblast whole-cell lysates. 
Briefly, cell lysates were boiled and proteins were separated using SDS-PAGE 
with precast 10% polyacrylamide gels (Bio-Rad) suspended in 5x tris/glycine 
(125 mM Tris-HCL, 1 M Glycine, 0.5% (w/v) SDS) running buffer. Each lane was 
loaded with 25 µL of protein extract, and subsequent analyses were performed 
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by normalizing each blot to the concentration of soluble protein loaded. Purified 
eNOS (Calbiochem) was used as the positive control for each gel/blot. The gels 
were transferred to polyvinyldene fluoride membranes (Fisher) using a semi-dry 
transfer apparatus with optimal transfer at 15 V for 30 minutes using a 
tris/glycine/methanol transfer buffer (25 mM Tris, 192 mM glycine, 10% 
methanol). Each membrane was then stained with 0.1% (w/v) Ponceau-S stain to 
ensure successful transfer. Membranes were then blocked overnight in 5% 
nonfat dry milk/PBS at room temperature. After blocking, membranes were 
washed with 1% milk/PBS/0.1% Tween-20 and primary antibody was added at 
appropriate working dilution, using 1% milk/PBS/0.1% T-20 as diluents. Primary 
antibodies were diluted follows: 
o PCNA monoclonal (Santa Cruz) 1:200 
o native eNOS polyclonal (BD Biosciences) 1:200  
o phospho-eNOS Ser1177 polyclonal (Santa Cruz) 1:200 
o phospho-eNOS Thr495 polyclonal (Santa Cruz) 1:200 
Primary antibody was allowed to incubate on the membrane for 1-2 hours at 
room temperature or overnight at 4˚C. All subsequent washes and secondary 
antibody dilution was carried out with 1%milk/PBS/0.1% T-20. Horseradish 
peroxidase-conjugated secondary antibody (Southern Biotech) was allowed to 
incubate at appropriate dilution on blot for 30 minutes at room temperature. 
Visualization of membrane(s) was accomplished using ECL chemiluminescent 
detection (GE Healthcare) and the Alpha-Innotech Fluorochem HD2 Gel Imaging 
System.  
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Densitometry analysis 
 Quantitative analysis of the western blots was performed using 
densitometry analysis of the pixel densities of each visible band after 
chemiluminescent staining. Initially, the local background of the band was 
subtracted from the pixel density value, and then normalized to the protein 
concentration loaded to give relative density.  
 
Immunofluorescence Microscopy  
 Fibroblasts were trypsinized from a 100 mm dish when they reached ~70  
-80% confluence and seeded onto 24-well plates containing one round 
microscopic cover slip per well at a density of 4-8 x 105 cells/500 µl per well. 
Cells were then allowed to incubate in CO2 incubator for 4-6 hours to adhere to 
cover slips, or 24 hours if a higher confluence was desired. After incubation, and 
if applicable, media was aspirated and replaced with fresh media containing 
appropriate treatments. After the 24 hour treatment, cover slips were washed 
with sterile PBS and fixed for 5 minutes using an ice cold mixture of 70% 
methanol + 30% acetone. After fixation, cells were washed with PBS and blocked 
overnight using 10% goat serum. The next day, the coverslips were washed four 
times with PBS to remove excess blocking serum. eNOS polyclonal antibody (BD 
Biosciences) was diluted 1:50 in 1% goat serum and incubated for one hour at 
room temperature. After primary incubation, cells were washed three times each 
with 1% milk/PBS/0.1% T-20. An IgG secondary antibody (Santa Cruz) 
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conjugated to a Texas Red fluorophore was added at a 1:1000 dilution and the 
cover slips were incubated for 30 minutes at room temperature. The washing 
step was then repeated and cells were mounted on microscope slides using 
Prolong Antifade (Invitrogen) and allowed to dry overnight at room temperature. 
Low power images (20x objective) were visualized using the differential 
interference contrast and DAPI filters of a Zeiss Axioplan-2 epifluorescent 
microscope. Photographs were then captured using a high power (40x objective) 
oil-immersion filter and an AxioCam MRm camera and associated software.   
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RESULTS 
 
eNOS localization is dependent upon cellular differentiation 
 Primary lung fibroblasts were isolated and cultured from Lewis rats and 
used in all subsequent experiments. The cultured cells were grown under normal 
growth conditions (DMEM media supplemented with 10% FBS), and then serum 
starved for 24 hours to differentiate the cells. For simplification and consistency, 
all cells grown under normal conditions will be referred to as protomyofibroblasts, 
while those grown under serum-starvation conditions will be referred to as 
myofibroblasts. All cells were between passages two and five when used. In 
order to investigate eNOS localization under both normal and differentiated 
conditions, fixed cells were probed with an anti-eNOS primary antibody and 
Marina Blue-conjugated secondary antibody. As shown below in Figure 4A and 
4B, eNOS is localized primarily in the nucleus of protomyofibroblasts yet in 
myofibroblasts eNOS is expressed in the perinuclear/cytoplasmic region of the 
cells (Figure 4C). Figure 4D are cells grown on coverslips and stained with the 
secondary antibody only. 
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Figure 4: eNOS localization is dependent upon cellular differentiation. Pulmonary 
myofibroblasts were grown in DMEM supplemented with 10% FBS (A & B) or 
DMEM with no FBS (C)‡ and then probed with an anti-eNOS primary antibody 
and a Marina Blue-conjugated secondary antibody. D: Cells stained with 
secondary antibody alone. 
‡It has previously been shown that serum starvation results in a protomyofibroblast to myofibroblast 
transition characterized by skeletal protein expression (Rice & Leinwand, 2002). 
 
eNOS localization and activity are correlated 
 Based on the observation that eNOS localization changes in response to 
cell differentiation, we hypothesized that eNOS translocation would also correlate 
with the catalytic synthesis of NO in either the nucleus or cytoplasm of the cell. 
Intracellular levels of NO are qualitatively detectable by immunostaining fixed 
cells with 4,5-diaminofluorescein-2 diacetate (DAF-2DA) (Leikert et al., 2001; 
Schwendemann et al., 2008). DAF-2DA is a membrane-permeable fluorescein 
chromophore that is hydrolyzed to DAF-2 and trapped within the cell where it 
binds to NO and allows visualization by fluorescence microscopy. As shown in 
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Figure 5A, treating protomyofibroblasts with 10 µM DAF-2DA stain (Sigma) 
reveals NO synthesis to be localized primarily to the nucleus, while treated 
myofibroblasts (Figure 5B) display NO in the perinuclear region of the cell 
(experiments performed by Ms. Naomi Rowland). Previous data has suggested 
that eNOS is regulated by multiple mechanisms, including Ca2+/calmodulin 
binding (Boo et al., 2006). Therefore to investigate the role of Ca2+ on eNOS 
activity in the cells, both protomyofibroblasts and myofibroblasts were also 
treated with 1 mM of the calcium chelator EGTA. As shown in Figure 5 as well,  
intracellular Ca2+ does influence eNOS activity and localization; most 
significantly, the chelation of intracellular Ca2+ in protomyofibroblasts causes 
eNOS translocation to mimic that of differentiated myofibroblasts by moving from 
the nucleus to the perinuclear region (Figure 5C). Catalytic activity of eNOS in 
myofibroblasts (Figure 5D) does not appear to be affected by EGTA treatment.  
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Figure 5: eNOS localization and activity are coordinated A: Protomyofibroblasts 
stained with DAF-2DA. B: Myofibroblasts stained with DAF-2DA C: 
Protomyofibroblasts + 1 mM EGTA stained with DAF-2DA D: Myofibroblasts + 1 
mM EGTA stained with DAF-2DA.   
 
 
eNOS is expressed in the nucleus in both protomyofibroblasts and 
myofibroblasts 
 In order to more thoroughly quantify eNOS localization and eventually 
activity, fractionation and immunoblot analysis was used in cells grown under 
normal and differentiated conditions. Initially, successful fractionation into nuclear 
and cytoplasmic components was confirmed by probing western blots with an 
antibody directed at PCNA (Figure 6a and 6b). Nuclear fractions show bands 
around the 30 kDa ladder marking, correlating with the 35 kDa size of PCNA 
(Figure 6a). Cytoplasmic fractions probed with anti-PCNA antibody show no 
bands at the 35 kDa region, confirming cells were adequately separated into 
nuclear and cytoplasmic fractions.  
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Figure 6: Cellular fractionation is confirmed by presence of PCNA in the nucleus 
A: (Nuclear fractions) B: (cytoplasmic fractions): Cytoplasmic fractions: Lane e: 
purified eNOS; Lane 1: Myofibroblasts- untreated; Lane 2: Protomyofibroblasts- 
untreated; Lane 3: Myofibroblasts- + PMA; Lane 4: Protomyofibroblasts + PMA; 
Lane 5: Myofibroblasts- + PMA & EGTA; Lane 6: Protomyofibroblasts + PMA & 
EGTA  
  
 Following confirmation of successful fractionation, both nuclear and 
cytoplasmic extracts were probed with an anti-eNOS polyclonal antibody. As 
shown in Figure 7 lanes one and two, protomyofibroblasts and myofibroblasts 
express eNOS in the nucleus.  Densitometry analysis (Figure 8), followed by 
normalization to protein concentration, suggests that nuclear eNOS expression 
appears higher in differentiated myofibroblasts than protomyofibroblasts, 
although the difference could not be statistically confirmed. Results are in 
agreement with previous experiments showing nuclear staining in myofibroblasts, 
and to a less extent protomyofibroblasts, although no cytoplasmic eNOS staining 
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was observed for any sample tested (data not shown) when expression levels 
were quantified by densitometry.    Previous investigations in our lab have shown the expression and activity 
of eNOS can be regulated by increasing or decreasing the levels of intracellular 
Ca2+, although it isn’t clear if Ca2+ is acting directly on eNOS or upstream through 
the activation of Ca2+-regulated signaling pathways (unpublished results). 
Indeed, it appears the expression and activity of eNOS can be regulated 
independently of Ca2+ as well, via the phosphorylation of Ser1177 (Fleming et al., 
2001). Moreover, Ca2+-dependent, PKC agonist-induced activation of eNOS, 
resulting in the phosphorylation of Thr495 in the CaM-binding domain of the 
protein, has also been reported to downregulate expression and catalytic activity 
of the protein (Chen et al., 1999).  
 To further investigate the role of upstream Ca2+ signaling pathways in 
regulating eNOS localization, cells were treated with 10 µM of the PKC activator 
PMA. Additionally as a control, 150 µM EGTA was added to the cells treated with 
PMA to mitigate the effects of the agonist. In Figure 7, lanes three and four show 
myofibroblasts and protomyofibroblasts, respectively, treated with PMA. Lanes 
five and six show myofibroblasts and protomyofibroblasts treated with PMA and 
EGTA.  
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Figure 7: eNOS expression is differentially regulated by Ca2+ in 
protomyofibroblasts versus myofibroblasts. Western blot showing nuclear 
fractions of treated and untreated cells. Lane 1: Myofibroblasts, no treatment; 
Lane 2: Protomyofibroblasts, no treatment; Lane 3: Myofibroblasts treated with 
10 µM PMA; Lane 4: Protomyofibroblasts treated with 10 µM PMA; Lane 5: 
Myofibroblasts treated with 10 µM PMA and 150 µM EGTA; Lane 6: 
Protomyofibroblasts treated with 10 µM PMA and 150 µM EGTA. This blot 
represents the results of one experiment.  
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Figure 8: Densitometry analysis of Figure 7. Pixel densities normalized to local 
background of each boxed lane (Figure 7) and amount of protein loaded per well, 
grouped according to treatment. 1- Myofibroblasts, no treatment; 2- 
Myofibroblasts + PMA; 3- Myofibroblasts + PMA & EGTA; 4- 
Protomyofibroblasts, no treatment; 5- Protomyofibroblasts + PMA; 6- 
Protomyofibroblasts + PMA & EGTA   
  
 Results indicate that when differentiated myofibroblasts are treated with 
PMA, eNOS expression decreases (Figures 7 and 8). Chelation of Ca2+ results in 
the return of normal eNOS expression levels. Protomyofibroblasts do not 
respond the same way to PKC activation. eNOS expression is slightly increased 
in response to PMA treatment in these cells  
 It is reported that eNOS becomes less active if phosphorylated on Thr495 
by PKC (Chen et al., 1999), as Thr495 phosphorylation may interfere with CaM 
binding to the enzyme at low Ca2+ concentrations. After probing our previous 
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immunoblotted cell fractions with native eNOS the membranes were stripped of 
their antibodies and a polyclonal enzyme specific for phospho-eNOS (Thr495) was 
used to analyze whether or not this residue is phosphorylated in PMA-treated 
pulmonary myofibroblasts. Results indicate that Thr495 is not phosphorylated in 
either the cytoplasmic or nuclear fractions in either protomyofibroblasts or 
myofibroblasts. Therefore this particular residue is not implicated in the 
attenutation of activity or change in expression of the eNOS in our cells.It is 
possible the polyclonal antibody was not specific to this residue, as it differs in its 
primary sequence position among mammals expressing the enzyme (ex: bovine 
eNOS is phosphorylated on Thr495, while human eNOS is phosphorylated on 
Thr497).  Phosphorylation on Ser116 has been demonstrated to be inhibited by the 
PKC inhibitor calphostin (Kou et al., 2002), suggesting other residues are 
regulated by PKC activation and warrant further investigation.    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Figure 9: Phospho-eNOS (Thr495) immunoblots of nuclear and cytoplasmic 
fractions. Nuclear fractions (Figure 9A) reprobed with anti-phosphorylated eNOS 
(Thr495). “L” indicates the ladder band and “e” indicates the purified eNOS used 
as a control. Figure 9B indicates cytoplasmic fractions.  
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DISCUSSION 
 
 In recent years, the theory of IPF as a disease consisting predominantly of 
chronic and uncontrolled inflammation has largely been dismissed as being 
inaccurate. While many interstitial lung diseases include an identifiable initial 
inflammatory response to a damaging agent, many patients heal or show vast 
improvement with anti-inflammatory therapies (Selman & Pardo, 2002). The 
evolution of the initial inflammatory response to the fibroproliferative pathology 
characteristic of IPF is largely indistinguishable upon lung biopsy to that of other 
interstitial lung diseases. Moreover, there is little evidence to suggest true IPF 
begins with an inflammatory response, or support for the theory that inflammation 
is prominent in the early phases of IPF (Bjoraker et al., 1998). Indeed, the lack of 
long-term beneficial response to anti-inflammatory drugs, corticosteroids, and 
immunosuppressive agents among patients suggests the mechanism behind the 
onset and fibroproliferative nature of IPF lies in a realm science just beginning to 
to be understood.  
 The focus of current research into IPF has generally centered on it as 
being a disease of fibroproliferation preceded by alveolar cell activation (Selman 
& Pardo, 2002). Both of these factors have been shown to trigger a number of 
chemokines/growth factors that induce fibroblast migration and proliferation, and 
differentiation among myofibroblasts, and subsequent accumulation of ECM 
(Ramos-Nino et al., 2003: IPF Supplement). It’s important to recognize that the 
potential inflammation and fibroproliferation seen in IPF are two 
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pathophysiologically distinct pathways independent of each other. Novel 
treatments and anti-fibrotic therapies are currently in various stages of 
preclinical/clinical development (de Andrade & Thannickal, 2009) and take aim at 
the underlying fibroproliferation that is now known to be the hallmark of the 
disease.  
  A consistent finding from the various studies into the cell biology, growth-
factor/cytokine signaling, animal models, and human models of IPF is the 
accumulation of the aggregates of myofibroblasts in the fibroblastic foci of the 
tissue (Thannickal and Horowitz, 2006). Ample evidence exists showing the 
development of apoptosis-resistant phenotypes of myofibroblasts are generated 
during fibroblast/myofibroblast differentiation in disease models of IPF, with a 
correlation among the extent of the fibrotic foci and increased rates of mortality.  
 Nitric oxide, generated by NOS, plays a substantial role as a signaling 
molecule involved in physiological processes in the airway epithelium (Gaston et 
al., 1994; Barnes, 1995). The endothelial isoform of NOS (eNOS) has been 
demonstrated to be a key enzyme in endothelial tissue homeostasis, 
angiogenesis, and remodeling. In the last few years, and in this present study, 
the goal of our research lab has been to characterize and investigate the factors 
regulating eNOS (as well as iNOS) expression and activity, including post- 
translational modifications of the enzyme, protein-protein interactions, cofactors, 
Ca2+/CaM influences, and phosphorylation.  
 There has been a large amount of research into the biochemical 
properties of eNOS in a number of endothelial cell types, namely bovine aortic 
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endothelial cells. Alternatively, there is little research into the enzyme’s 
expression in mesenchymal cells such as pulmonary myofibroblasts, the focus of 
this thesis. Indeed, a PubMed search of “nitric oxide” and “pulmonary 
myofibroblast” yields only nine results, while one of “nitric oxide” “bovine aortic 
endothelial cell” yields 174.  
 Nitric oxide has been shown to attenuate the epithelial-mesenchymal 
transition induced by TGF-β in alveolar epithelial cells both in vivo and in vitro. 
This feature is also seen in pulmonary tissue biopsies of those patients with lung 
fibrosis secondary to myofibroblast-mediated excessive ECM deposition (Vyas-
Read et al., 2006). Additionally, inhibition of NO synthesis has been shown to 
increase accumulation of myofibroblasts and subsequent collagen deposition 
(Pessanh et al., 2000).  
 This study presents a potential mechanism by which nitric oxide influences 
myofibroblast accumulation by investigating the role of eNOS in the pulmonary 
myofibroblast. eNOS knockout mice experience prolonged pulmonary fibrosis in 
response to the profibrotic agent bleomycin, suggesting a correlation between 
eNOS expression and myofibroblast regulation and/or apoptosis. We have 
demonstrated eNOS is the primary NOS isoform expressed in pulmonary 
myofibroblasts and the enzyme’s localization is dependent upon growth 
conditions. Immunocytochemistry of prtotmyofibroblasts grown under normal 
(10% FBS) conditions predominately show eNOS expression confined to the 
nucleus, with little cytosolic staining. Myofibroblasts grown under serum-starved 
conditions (0% FBS) show an increase in α-SMA and MyHC expression and 
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mimic in vivo differentiated conditions (Rice and Leinwand, 2003).  eNOS is 
translocated from the nuclear to cytoplasmic regions under these highly 
differentiated conditions (see Figure 4), although nuclear staining is still 
observed, as shown in figure 7.  
 In epithelial cells, eNOS has been shown to translocate from the caveolae 
to intracellular sites in a Ca2+- dependent manner (Goetz et al., 1999). I have 
shown this too, is the case for pulmonary myofibroblasts. Removal of Ca2+ from 
cells by the chelator EGTA mimics a differentiated state, with eNOS expression 
largely confined to the perinuclear region. Previous research indicating increases 
in cytoplasmic Ca2+ levels activates CaM, which binds to the canonical CaM-
binding domain in eNOS to promote the alignment of the oxygenase and 
reductase domains of the enzyme, leading to an increase in catalytic activity 
(Sessa, 2004; Fleming et al., 2001). My data shows pulmonary myofibroblasts 
respond oppositely to Ca2+ presence, with a decrease in basal catalytic activity  
upon by the removal of Ca2+.   
 There is ample evidence that regulation of eNOS localization, and, 
coordinately, activity is regulated via phosphorylation/dephosphorylation on 
multiple serine, tyrosine, and threonine residues by various protein kinases and 
phosphatases (Dimmeler et al., 1999; Gallis et al., 1999; Michell et al., 2001). 
Neuronal NOS (nNOS) was the first NOS isoform to be identified as 
phosphorylated at distinct sites by PKC, and PKC-dependent phosphorylation 
decreased the level of enzyme activity (Bredt et al., 1992). We investigated the 
role of PKC-dependent phosphorylation on eNOS localization and activity by 
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treating cells with the known PKC activator PMA and immunoblotting fractionated 
cell lysates for native eNOS and phospho-eNOS (Thr495). PKC activation by PMA 
has previously been shown to inhibit eNOS activity in cultured cells (Davda et al., 
1994; Hirata et al., 1995). In Figure 9, we show that myofibroblasts treated with 
PMA do indeed synthesize lower than basal levels of eNOS, with the additions of 
EGTA mitigating this effect. Protomyofibroblasts do not appear to be affected by 
PMA treatment in the same way showing slight increases in expression.  By 
DAF-2DA staining, we have been also able to show qualitatively that NO is also 
present in the same cellular regions as eNOS.  This work is in agreement with 
recent work in our lab by Dr. Bethel Sharma who has able to quantify NO activity 
in our cells grown under various conditions. NO production was measured 
amperometrically using an NO electrode (Innovative Instruments, Inc) and 
normalized to total cell count. Treatment with 10 µM PMA was found to lower NO 
production to near basal levels of differentiated cells. Addition of EGTA to the 
PMA-treated differentiated cells restored NO production, providing confirmation 
that phosphorylation of eNOS by PKC is associated with a reduction in its 
catalytic activity in pulmonary myofibroblasts. Thus, the changes in eNOS 
expression in response to PKC activation (Figure 8) correlate with changes in the 
catalytic activity of the protein (Figure 10). These finding are in accordance with 
earlier data showing eNOS is a PKC substrate and PKC-mediated 
phosphorylation mitigates eNOS activity (Tsukahara et al., 1993; Davda et al., 
1994., Hirata et al., 1995; Fleming et al., 2001).  
 
   38 
 
Figure 10: PKC-induced phosphorylation coordinates with activity   
  
  These past and present studies have aided in analyzing the role 
nitric oxide plays as a signaling molecule in the pulmonary myofibroblast, a cell 
model with little background work, but with important research and clinical 
implications. With IPF being a disease of uncontrolled fibroproliferation, the 
possibility of using agents that alter collagen synthesis or mitigate other fibrotic 
responses are current focuses of first-line treatment for those unresponsive to 
conventional therapies. With its ability to inhibit microtubule polymerization, 
colchicine has been investigated in vitro and in animal models and demonstrated 
an ability to suppress the release of macrophage-derived growth factor and 
fibronectin by cultured alveolar macrophages from patients with sarcoidosis and 
IPF (Rennard et al., 1988) Treatment with interferon-γ is another novel anti-
fibrotic with potential benefits to those with IPF. Ziesche and colleagues have 
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demonstrated interferon-γ inhibits the proliferation of lung fibrosis in a dose-
dependent manner and reduces the synthesis of protein in fibroblasts (Ziesche et 
al., 1999). Future studies are needed to gain insight into the role nitric oxide 
plays in the fibroproliferative properties of this cell as implicated in IPF. With the 
number of existing NO donating or inhibiting pharmaceuticals, the NO pathway 
could yield yet more treatment options for a disease that, thus far, has tragic 
consequences.  
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